Related Experiment Video
Updated: Jun 6, 2026
06:19
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Multiple subconjunctival bevacizumab for advanced primary pterygium.
Sandeep Saxena1, Kuldeep Vishwkarma, Mohit Khattri
1Department of Ophthalmology, CSM Medical University, Lucknow, 226018, India. sandeepsaxena2020@yahoo.com
Annals of Ophthalmology (Skokie, Ill.)
|December 9, 2010
Summary
Multiple subconjunctival bevacizumab injections effectively treated advanced primary pterygium, improving vision. This study demonstrates the potential of off-label bevacizumab for pterygium regression and visual acuity enhancement.
Area of Science:
- Ophthalmology
- Vascular Biology
- Regenerative Medicine
Background:
- Primary pterygium is a common ocular condition that can impair vision.
- Current treatments for advanced pterygium have limitations.
- Bevacizumab, a vascular endothelial growth factor inhibitor, is used off-label in ophthalmology.
Observation:
- This study investigated the efficacy of multiple subconjunctival bevacizumab injections for advanced primary pterygium.
- The treatment involved repeated injections of bevacizumab into the subconjunctival space.
Findings:
- Subconjunctival bevacizumab injections led to significant pterygium regression.
- Best-corrected visual acuity improved from 20/100 to 20/60 at the 6-month follow-up.
- The treatment was effective in managing advanced primary pterygium.
Implications:
- Subconjunctival bevacizumab represents a promising therapeutic option for advanced primary pterygium.
- Further research is warranted to establish optimal dosing and long-term outcomes.
- This approach may offer a less invasive alternative to surgical interventions.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...